Morning Market Losers
June 03, 2013 at 09:55 AM EDT
Synta Pharmaceuticals (NASDAQ: SNTA ) shares dipped 32.93% to $4.95 after the company reported positive overall survival results from GALAXY-1 Phase 2b/3 trial of ganetespib in second-line non-small cell lung cancer. Infinity Pharmaceuticals (NASDAQ: INFI ) shares lost 23.41% to $20.64 on Phase 1 data. Affymax (NASDAQ:
